These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8479100)

  • 1. [Basic study of CA549, a new tumor marker for breast cancer, and evaluation of its clinical usefulness].
    Yamaguchi A; Ushigome M; Imai T; Otake H; Igarashi H; Hatori N; Tomiyoshi K; Inoue T; Endo K
    Kaku Igaku; 1993 Mar; 30(3):317-22. PubMed ID: 8479100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
    Gion M; Plebani M; Mione R; Penzo C; Meo S; Burlina A
    Br J Cancer; 1994 Apr; 69(4):721-5. PubMed ID: 8142260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA549 and TPS patterns in the diagnosis and staging of patients with breast carcinoma.
    Vibert HG; Houston AS; Wilkins GP; Kemp PM; Macleod MA
    Int J Biol Markers; 1996; 11(4):198-202. PubMed ID: 9017442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the circulating glycoprotein CA549 in mammary cancer and other malignancies.
    Clocchiatti L; De Biasi F; Cartei G; Sibau A; Vigevani E; Signor M; Giovannoni M; Ceschia V; Di Chiara F; Grandis S
    Tumori; 1991 Oct; 77(5):395-8. PubMed ID: 1781036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The correlation between the immunohistochemical expression of DF3 antigen and serum CA15-3 in breast cancer patients.
    Ohuchi N; Sato S; Akimoto M; Taira Y; Matoba N; Takahashi K; Mori S
    Jpn J Surg; 1991 Mar; 21(2):129-37. PubMed ID: 1646903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Basic and clinical studies of serum CA195 antigen assay with "BL-CA195" kit].
    Kobayashi M; Yamaguchi A; Imai T; Otake H; Igarashi H; Hatori N; Tomiyoshi K; Inoue T; Endo K; Sakahara H
    Kaku Igaku; 1993 Apr; 30(4):441-7. PubMed ID: 8315895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
    Nicolini A; Ferdeghini M; Colombini C; Carpi A
    J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A study of the clinical usefulness of the CA15-3 radioimmunoassay kit].
    Abe Y; Odagiri E; Jibiki K; Demura R; Demura H
    Gan No Rinsho; 1988 Oct; 34(12):1672-6. PubMed ID: 3193612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ca549 immunoassay in breast-tissue - comparison with ca15.3 and mca.
    Gion M; Plebani M; Mione R; Capitanio G; Penzo C; Meo S
    Int J Oncol; 1993 Oct; 3(4):695-9. PubMed ID: 21573420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer marker Ca549. A multicenter study.
    Chan DW; Beveridge RA; Bhargava A; Wilcox PM; Kennedy MJ; Schwartz MK
    Am J Clin Pathol; 1994 Apr; 101(4):465-70. PubMed ID: 8160638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
    Gion M; Mione R; Nascimben O; Valsecchi M; Gatti C; Leon A; Bruscagnin G
    Br J Cancer; 1991 May; 63(5):809-13. PubMed ID: 2039707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of four monoclonal antibodies as serum markers in breast cancer.
    Robertson JF; Pearson D; Price MR; Selby C; Badley RA; Pearson J; Blamey RW; Howell A
    Eur J Cancer; 1990; 26(11-12):1127-32. PubMed ID: 2149994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CA15-3 tumor marker in early detection of breast cancer].
    Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
    Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer.
    Sacks NP; Stacker SA; Thompson CH; Collins JP; Russell IS; Sullivan JA; McKenzie IF
    Br J Cancer; 1987 Dec; 56(6):820-4. PubMed ID: 2449238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
    Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
    Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer.
    Nicolini A; Ferrari P; Rossi G
    Adv Exp Med Biol; 2015; 867():197-225. PubMed ID: 26530368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical value of serum CA15-3 assay postoperatively in breast cancer patients.
    Kobayashi S; Iwase H; Karamatsu S; Matsuo K; Masaoka A; Miyagawa T
    Jpn J Surg; 1989 May; 19(3):278-82. PubMed ID: 2779026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of tumor marker CA15-3 in breast cancer].
    Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
    Barak V; Carlin D; Sulkes A; Treves A; Biran S
    Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.